Cost-utility analysis of palivizumab in Italy: results from a simulation model in the prophylaxis of respiratory syncytial virus infection (RSV) among high-risk preterm infants (Q37205038)

From Wikidata

Jump to navigation Jump to search

scientific article published on 25 February 2009

Language	Label	Description	Also known as
English	Cost-utility analysis of palivizumab in Italy: results from a simulation model in the prophylaxis of respiratory syncytial virus infection (RSV) among high-risk preterm infants	scientific article published on 25 February 2009

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Cost-utility analysis of palivizumab in Italy: results from a simulation model in the prophylaxis of respiratory syncytial virus infection (RSV) among high-risk preterm infants (English)

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

0 references

0 references

author name string

Gaetano Chirico

1

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Roberto Ravasio

2

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Urbano Sbarigia

3

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

25 February 2009

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Italian Journal of Paediatrics

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

35

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

1

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

4

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Changing health environment: the challenge to demonstrate cost-effectiveness of new compounds

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2687544

6 September 2017

Health care utilisation of prematurely born, preschool children related to hospitalisation for RSV infection

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2687544

6 September 2017

Seasonality of long term wheezing following respiratory syncytial virus lower respiratory tract infection

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2687544

6 September 2017

Respiratory syncytial virus infection

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2687544

6 September 2017

Five‐Hundred Life‐Saving Interventions and Their Cost‐Effectiveness

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2687544

6 September 2017

Cost effectiveness of palivizumab for respiratory syncytial virus prophylaxis in high-risk children: a UK analysis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2687544

14 September 2017

Morbidity and mortality after RSV-associated hospitalizations among premature Canadian infants

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2687544

14 September 2017

Safety and pharmacokinetics of an intramuscular humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia. The MEDI-493 Study Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2687544

26 June 2018

Development of a Humanized Monoclonal Antibody (MEDI‐493) with Potent In Vitro and In Vivo Activity against Respiratory Syncytial Virus

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2687544

26 June 2018

Palivizumab prophylaxis, respiratory syncytial virus, and subsequent recurrent wheezing

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2687544

3 September 2018

Hospitalization for RSV bronchiolitis before 12 months of age and subsequent asthma, atopy and wheeze: a longitudinal birth cohort study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2687544

3 September 2018

Severe respiratory syncytial virus bronchiolitis in infancy and asthma and allergy at age 13.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2687544

3 September 2018

Respiratory morbidity 20 years after RSV infection in infancy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2687544

3 September 2018

Respiratory syncytial virus bronchiolitis in infancy is an important risk factor for asthma and allergy at age 7.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2687544

3 September 2018

Respiratory syncytial virus in early life and risk of wheeze and allergy by age 13 years

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2687544

3 September 2018

Safety, tolerance and pharmacokinetics of a humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2687544

3 September 2018

Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/19490659

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cost-effectiveness analysis of palivizumab in premature infants without chronic lung disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/19490659

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cost-effectiveness analysis and the consistency of decision making: evidence from pharmaceutical reimbursement in australia (1991 to 1996)

1 reference

https://pubmed.ncbi.nlm.nih.gov/19490659

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

[The efficiency (cost-effectiveness) of palivizumab as prophylaxis against respiratory syncytial virus infection in premature infants with a gestational age of 32-35 weeks in Spain]

1 reference

https://pubmed.ncbi.nlm.nih.gov/19490659

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Multiattribute utility function for a comprehensive health status classification system. Health Utilities Index Mark 2

1 reference

https://pubmed.ncbi.nlm.nih.gov/19490659

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The economic burden of asthma in US children: estimates from the National Medical Expenditure Survey

1 reference

https://pubmed.ncbi.nlm.nih.gov/19490659

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1186/1824-7288-35-4

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Dimensions Publication ID

0 references

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37205038&oldid=2200022917"